The compound was administered to chicks that had been infected with Infectious Bronchitis Virus (IBV). The data from the study indicated that QR448(a) is efficacious against an IBV challenge in two week old specific pathogen free (SPF) chicks, confirming previous results indicating that treatment with QR448(a) before or after viral exposure has the potential to lessen or prevent disease.

Preventing and treating infectious bronchitis caused by IBV is a worldwide concern of the poultry industry which calculates its loses due to this disease in lowered weight gains and feed efficiency in broilers, lowered production and quality of eggs in layers and breeders, mortality, clean-up costs and disruption to operations.

The Company initiated its investigations into the effectiveness of this compound based on feedback from poultry industry leaders who expressed an increasing need for additional products to combat Infectious Bronchitis (IBV).

Dr Richard Rosenbloom, Executive Vice President and Chief Operating Officer of Quigley Pharma stated: "With the increased emphasis by the animal health community on prevention as well as treatment of disease, the results from our experiments in chickens have demonstrated that our QR448(a) compound can prevent as well as treat 2 week old SPF chicks from infection when challenged with IBV in a dose response experimental design. We believe this innovative, non-vaccine, broad spectrum antiviral has the potential to offer the poultry industry a natural base solution to this growing problem."

With the completion of this latest study and the current dossier of data the company plans to solicit the poultry industry for additional guidance and potential interest and opportunities for developing this compound jointly toward commercialization.